A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Mar 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Giredestrant (Primary)
Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
Focus First in man; Therapeutic Use
Sponsors Genentech

15 Jun 2021 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Interim results (n=45) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
12 May 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com